/
RSS Feed
Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York
David Maloney
Nonmyeloablative Alogeneic Transplants Ready for Prime-Time in Follicular Lymphoma?
David Maloney, Fred Hutchinson Cancer Research Center, Seattle
Allogeneic transplantation is now a good option for treating some patient groups with follicular lymphoma. David Maloney explained to Peter Goodwin in Paris how his group has harnessed graft-versus-tumor effect by using nonmyeloablative conditioning without causing unacceptable risks of graft-versus-host disease.
Allogeneic transplantation is now a good option for treating some patient groups with follicular lymphoma. David Maloney explained to Peter Goodwin in Paris how his group has harnessed graft-versus-tumor effect by using nonmyeloablative conditioning without causing unacceptable risks of graft-versus-host disease.
Carolyn Krasner
Trabectedin Activity in Platinum-Sensitive Relapsed Ovarian Cancer
Carolyn Krasner, Massachusetts General Hospital, Boston
Could trabectedin, which has a novel mechanism of action, be a useful agent for patients with relapsed ovarian cancer? Derek Thorne discussed this question in New York with Carolyn Krasner, whose data show the greatest benefit in patients who are sensitive to platinum agents.
Could trabectedin, which has a novel mechanism of action, be a useful agent for patients with relapsed ovarian cancer? Derek Thorne discussed this question in New York with Carolyn Krasner, whose data show the greatest benefit in patients who are sensitive to platinum agents.
Kirk Schultz
Armand Keating
High-Dose Chemotherapy Plus Imatinib Benefits Pediatric Acute Lymphoblastic Leukemia
Kirk Schultz, British Columbia Children’s Hospital, Vancouver
COMMENT: Armand Keating, Princess Margaret Hospital, Toronto
For children with acute lymphoblastic leukemia, high-dose chemotherapy combined with imatinib appears to show a survival benefit. Sarah Maxwell spoke with study author Kirk Schultz at the ASH meeting in Atlanta, and Armand Keating provided comment.
COMMENT: Armand Keating, Princess Margaret Hospital, Toronto
For children with acute lymphoblastic leukemia, high-dose chemotherapy combined with imatinib appears to show a survival benefit. Sarah Maxwell spoke with study author Kirk Schultz at the ASH meeting in Atlanta, and Armand Keating provided comment.
John Gribben
Chronic Lymphocytic Leukemia: New Options After Fludarabine Failure
John Gribben, Bartholemews Hospital, London
New treatments for chronic lymphocytic leukemia were discussed in Paris by John Gribben. He gave Peter Goodwin his assessment of antibody therapies such as rituximab and alemtuzumab and new drugs such as lenalidomide, and combinations including standard fludarabine therapy.
New treatments for chronic lymphocytic leukemia were discussed in Paris by John Gribben. He gave Peter Goodwin his assessment of antibody therapies such as rituximab and alemtuzumab and new drugs such as lenalidomide, and combinations including standard fludarabine therapy.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080315_ajoia.mp3]
To subscribe to the ASCO Audio Journal of Oncology podcast please go to ASCO Audio Journal of Oncology in Advance Presentations or click here.
